top of page

IPD

ImpediMed Ltd

Healthcare Equipment and Supplies

·

Healthcare

4

comments

3

fund managers

past 90 days

About ImpediMed Ltd

ImpediMed Ltd. develops and distributes medical bioimpedance spectroscopy devices for fluid status management. Its flagship product, SOZO, provides critical body composition data to assist clinicians in managing chronic diseases and improving patient outcomes. Founded in 1999 by Melvyn and Lucille Bridges, the company is headquartered in Pinkenba, Australia. ImpediMed focuses on leveraging advanced bioimpedance technology to support clinical decision-making and enhance healthcare delivery.

Commentary Volume

4

Comments

3

Fund managers

0

Past 90 days

SOURCE

ACTION

COMMENT PREVIEW

FUND MANAGER

DATE

Loading...

Source: Ipsum Capital Q4 Quarterly Letter  ·  Published 14 March 2025

Loading...

.

​Loading...

Loading...

Loading...

Loading...

Loading...

Source: Ipsum Capital Q4 Quarterly Letter  ·  Published 14 March 2025

Report a problem

Loading...

.

Loading...

Loading...

Loading...

Loading...

14 Mar 2025

ic

Ipsum Capital

"Lorem ipsum dolor sit amet...

Q4 Letter

14 Mar 2025

ic

Dolor Investments

"Lorem ipsum dolor sit amet...

Q4 Letter

🔒 21 more comments from 10 sources

Unlock full access

§ Important Notice

The entries below are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.

Commentary

Sector

Healthcare

Market cap

$1M

Fund managers

3 managers

First covered

31 Oct 2023

Last updated

30 Nov 2024

Company Details

Related Themes

ic

Ipsum Capital

6 comments

ic

Amet Funds

4 comments

ic

Dolor

3 comments

Top Investors Covering MIN

§ Reminder

The entries above are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.

Frequently asked questions about ImpediMed Ltd (ASX:IPD)

Frequently asked questions

Who is investing in ImpediMed Ltd (ASX:IPD)?

Fund managers including Monash Investors, QVG Capital and Lakehouse Capital have invested in ImpediMed Ltd (ASX:IPD).

What is the short interest in ImpediMed Ltd (ASX:IPD)?

The short interest in ImpediMed Ltd (ASX:IPD) is 0.62% which makes it the 262nd most shorted stock on the ASX. Of the 2.0B shares that ImpediMed Ltd has on issue, 12.7M have been sold short.

What does ImpediMed Ltd (ASX:IPD) do?

ImpediMed Ltd. develops and distributes medical bioimpedance spectroscopy devices for fluid status management. Its flagship product, SOZO, provides critical body composition data to assist clinicians in managing chronic diseases and improving patient outcomes. Founded in 1999 by Melvyn and Lucille Bridges, the company is headquartered in Pinkenba, Australia. ImpediMed focuses on leveraging advanced bioimpedance technology to support clinical decision-making and enhance healthcare delivery.

bottom of page